FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2888572800> ?p ?o ?g. }

• W2888572800 endingPage "898" @default.
• W2888572800 startingPage "887" @default.
• W2888572800 abstract "Background and AimsAssessment of disease activity is essential for developing and determining appropriate therapy in patients with ulcerative colitis (UC). Validated clinical and endoscopic scoring systems have been established to accurately define disease activity. Clinical and endoscopic treatment targets have also been proposed, with gastroenterologists encouraged to optimize medical therapy to achieve these targets. Recently, histology has been recognized as an important prognostic factor and potential treatment target in patients with UC.MethodsThis review summarizes the recent literature regarding histologic scoring indices in UC and offers practical guidance to gastroenterologists on how to interpret histologic data.ResultsSubstantial evidence indicates that histology accurately predicts clinical relapse, hospitalization, corticosteroid use, and development of dysplasia. Furthermore, compared with endoscopy, findings suggest that histology may be more predictive of these outcomes. Because microscopic disease activity can persist in the absence of clinical or endoscopic disease activity, histology may be the ideal marker of inflammation. Standardized definitions of histologic response and remission and a biopsy procurement protocol are needed to guide clinical decision making. It is recommended that overall assessment of disease severity be determined according to the worst affected biopsy fragment. Crypt architectural distortion, basal plasmacytosis, and neutrophilic activity should be reported. A 5-category classification system based on disease chronicity/activity and basal plasmacytosis is proposed. It is not yet necessary to report on the degree of mucosal eosinophilia or use a validated scoring system, although the latter may aid in determining therapeutic response.ConclusionsAlthough rarely used to measure inflammation and guide therapy, histologic disease activity is predictive of important clinical outcomes in UC. Randomized controlled trials are needed to determine whether histology should function as a treatment target. Assessment of disease activity is essential for developing and determining appropriate therapy in patients with ulcerative colitis (UC). Validated clinical and endoscopic scoring systems have been established to accurately define disease activity. Clinical and endoscopic treatment targets have also been proposed, with gastroenterologists encouraged to optimize medical therapy to achieve these targets. Recently, histology has been recognized as an important prognostic factor and potential treatment target in patients with UC. This review summarizes the recent literature regarding histologic scoring indices in UC and offers practical guidance to gastroenterologists on how to interpret histologic data. Substantial evidence indicates that histology accurately predicts clinical relapse, hospitalization, corticosteroid use, and development of dysplasia. Furthermore, compared with endoscopy, findings suggest that histology may be more predictive of these outcomes. Because microscopic disease activity can persist in the absence of clinical or endoscopic disease activity, histology may be the ideal marker of inflammation. Standardized definitions of histologic response and remission and a biopsy procurement protocol are needed to guide clinical decision making. It is recommended that overall assessment of disease severity be determined according to the worst affected biopsy fragment. Crypt architectural distortion, basal plasmacytosis, and neutrophilic activity should be reported. A 5-category classification system based on disease chronicity/activity and basal plasmacytosis is proposed. It is not yet necessary to report on the degree of mucosal eosinophilia or use a validated scoring system, although the latter may aid in determining therapeutic response. Although rarely used to measure inflammation and guide therapy, histologic disease activity is predictive of important clinical outcomes in UC. Randomized controlled trials are needed to determine whether histology should function as a treatment target." @default.
• W2888572800 created "2018-08-31" @default.
• W2888572800 creator A5012305407 @default.
• W2888572800 creator A5034135548 @default.
• W2888572800 creator A5035763230 @default.
• W2888572800 creator A5052596220 @default.
• W2888572800 creator A5055840412 @default.
• W2888572800 creator A5057225122 @default.
• W2888572800 date "2018-12-01" @default.
• W2888572800 modified "2023-10-17" @default.
• W2888572800 title "The emerging role of histologic disease activity assessment in ulcerative colitis" @default.
• W2888572800 cites W1492282569 @default.
• W2888572800 cites W1506122018 @default.
• W2888572800 cites W1929766967 @default.
• W2888572800 cites W1964102710 @default.
• W2888572800 cites W1965685585 @default.
• W2888572800 cites W1967714899 @default.
• W2888572800 cites W1974246098 @default.
• W2888572800 cites W1985687346 @default.
• W2888572800 cites W1986712043 @default.
• W2888572800 cites W1990397098 @default.
• W2888572800 cites W2001826686 @default.
• W2888572800 cites W2011361599 @default.
• W2888572800 cites W2030172587 @default.
• W2888572800 cites W2033497145 @default.
• W2888572800 cites W2036113015 @default.
• W2888572800 cites W2036760530 @default.
• W2888572800 cites W2043078815 @default.
• W2888572800 cites W2044963614 @default.
• W2888572800 cites W2056629400 @default.
• W2888572800 cites W2057618437 @default.
• W2888572800 cites W2065057455 @default.
• W2888572800 cites W2079332790 @default.
• W2888572800 cites W2080410907 @default.
• W2888572800 cites W2090665474 @default.
• W2888572800 cites W2103712425 @default.
• W2888572800 cites W2110052276 @default.
• W2888572800 cites W2116318925 @default.
• W2888572800 cites W2122443382 @default.
• W2888572800 cites W2131027745 @default.
• W2888572800 cites W2134883604 @default.
• W2888572800 cites W2149170290 @default.
• W2888572800 cites W2179998127 @default.
• W2888572800 cites W2233007555 @default.
• W2888572800 cites W2284831904 @default.
• W2888572800 cites W2296988598 @default.
• W2888572800 cites W2306466871 @default.
• W2888572800 cites W2321205867 @default.
• W2888572800 cites W2334551459 @default.
• W2888572800 cites W2346478945 @default.
• W2888572800 cites W2516545869 @default.
• W2888572800 cites W2518658233 @default.
• W2888572800 cites W2531437823 @default.
• W2888572800 cites W2550259131 @default.
• W2888572800 cites W2589294144 @default.
• W2888572800 cites W2611548364 @default.
• W2888572800 cites W2737243795 @default.
• W2888572800 cites W2749627335 @default.
• W2888572800 cites W2753613200 @default.
• W2888572800 cites W2783221675 @default.
• W2888572800 cites W2787397416 @default.
• W2888572800 cites W3142182956 @default.
• W2888572800 doi "https://doi.org/10.1016/j.gie.2018.08.018" @default.
• W2888572800 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30142351" @default.
• W2888572800 hasPublicationYear "2018" @default.
• W2888572800 type Work @default.
• W2888572800 sameAs 2888572800 @default.
• W2888572800 citedByCount "84" @default.
• W2888572800 countsByYear W28885728002019 @default.
• W2888572800 countsByYear W28885728002020 @default.
• W2888572800 countsByYear W28885728002021 @default.
• W2888572800 countsByYear W28885728002022 @default.
• W2888572800 countsByYear W28885728002023 @default.
• W2888572800 crossrefType "journal-article" @default.
• W2888572800 hasAuthorship W2888572800A5012305407 @default.
• W2888572800 hasAuthorship W2888572800A5034135548 @default.
• W2888572800 hasAuthorship W2888572800A5035763230 @default.
• W2888572800 hasAuthorship W2888572800A5052596220 @default.
• W2888572800 hasAuthorship W2888572800A5055840412 @default.
• W2888572800 hasAuthorship W2888572800A5057225122 @default.
• W2888572800 hasBestOaLocation W28885728001 @default.
• W2888572800 hasConcept C126322002 @default.
• W2888572800 hasConcept C126838900 @default.
• W2888572800 hasConcept C142724271 @default.
• W2888572800 hasConcept C2775894508 @default.
• W2888572800 hasConcept C2775934546 @default.
• W2888572800 hasConcept C2778260677 @default.
• W2888572800 hasConcept C2778451229 @default.
• W2888572800 hasConcept C2778709411 @default.
• W2888572800 hasConcept C2779134260 @default.
• W2888572800 hasConcept C2780007613 @default.
• W2888572800 hasConcept C2780479503 @default.
• W2888572800 hasConcept C57742111 @default.
• W2888572800 hasConcept C71924100 @default.
• W2888572800 hasConcept C90924648 @default.
• W2888572800 hasConceptScore W2888572800C126322002 @default.
• W2888572800 hasConceptScore W2888572800C126838900 @default.
• W2888572800 hasConceptScore W2888572800C142724271 @default.

• next